Nivolumab-话题@MedSci

#Nivolumab#

2篇内容 | 2093人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2208546, encodeId=c88e220854670, content=<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a> <a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a> <a href='/topic/show?id=30fc1282896' target=_blank style='color:#2F92EE;'>#Nivolumab#</a>, objectTitle=NEJM：Nivolumab联合Ipilimumab新辅助治疗黑色素瘤，半数人达到pCR（NADINA试验）, objectType=article, longId=828957, objectId=39bf82895e33, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240604/1717550685830_4754896.png, objectUrl=/article/show_article.do?id=39bf82895e33, replyNumber=0, likeNumber=121, createdTime=2024-06-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=39bf82895e33, moduleTitle=NEJM：Nivolumab联合Ipilimumab新辅助治疗黑色素瘤，半数人达到pCR（NADINA试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39bf82895e33)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2194301, encodeId=785e21943014c, content=<a href='/topic/show?id=11bee785311' target=_blank style='color:#2F92EE;'>#细胞因子释放综合征#</a> <a href='/topic/show?id=30fc1282896' target=_blank style='color:#2F92EE;'>#Nivolumab#</a> <a href='/topic/show?id=ef83112494fc' target=_blank style='color:#2F92EE;'>#ipillmumab#</a>, objectTitle=读书报告 | 化疗联合nivolumab和ipillmumab发生细胞因子释放综合征5例报道, objectType=article, longId=817557, objectId=ad5381e5572a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-is-working-at-the-hospital-P765AZE.jpg, objectUrl=/article/show_article.do?id=ad5381e5572a, replyNumber=0, likeNumber=75, createdTime=2024-03-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ad5381e5572a, moduleTitle=读书报告 | 化疗联合nivolumab和ipillmumab发生细胞因子释放综合征5例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad5381e5572a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2184496, encodeId=5dbf218449665, content=<a href='/topic/show?id=8f5c82594d5' target=_blank style='color:#2F92EE;'>#肾癌#</a> <a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a> <a href='/topic/show?id=30fc1282896' target=_blank style='color:#2F92EE;'>#Nivolumab#</a> <a href='/topic/show?id=c193110640f1' target=_blank style='color:#2F92EE;'>#ASCO GU 2024#</a>, objectTitle=ASCO GU 2024：Nivolumab/Ipilimumab在未经治疗的晚期或转移性RCC患者中显示出显著的生存获益（CheckMate-214研究）, objectType=article, longId=811385, objectId=df7281138559, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240128/1706443016945_8624274.png, objectUrl=/article/show_article.do?id=df7281138559, replyNumber=0, likeNumber=92, createdTime=2024-01-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=df7281138559, moduleTitle=ASCO GU 2024：Nivolumab/Ipilimumab在未经治疗的晚期或转移性RCC患者中显示出显著的生存获益（CheckMate-214研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df7281138559)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183199, encodeId=ab6d2183199f3, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a> <a href='/topic/show?id=30fc1282896' target=_blank style='color:#2F92EE;'>#Nivolumab#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#纳武利尤单抗#</a>, objectTitle=Blood Adv：Nivolumab联合剂量调整EPOCH一线治疗外周T细胞淋巴瘤：一项I期研究, objectType=article, longId=810515, objectId=082081051511, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240118/26de95a048a1484484f5970c501a52b6.jpg, objectUrl=/article/show_article.do?id=082081051511, replyNumber=0, likeNumber=82, createdTime=2024-01-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=082081051511, moduleTitle=Blood Adv：Nivolumab联合剂量调整EPOCH一线治疗外周T细胞淋巴瘤：一项I期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=082081051511)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2182844, encodeId=f1fa218284416, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a> <a href='/topic/show?id=30fc1282896' target=_blank style='color:#2F92EE;'>#Nivolumab#</a> <a href='/topic/show?id=7d8b689351' target=_blank style='color:#2F92EE;'>#EPOCH#</a>, objectTitle=Nivolumab联合剂量调整EPOCH一线治疗外周T细胞淋巴瘤：一项I期研究, objectType=article, longId=809530, objectId=75c780953086, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-examining-medical-report-PJUYHWX.jpg, objectUrl=/article/show_article.do?id=75c780953086, replyNumber=0, likeNumber=82, createdTime=2024-01-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=75c780953086, moduleTitle=Nivolumab联合剂量调整EPOCH一线治疗外周T细胞淋巴瘤：一项I期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75c780953086)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2176886, encodeId=b68421e6886bd, content=<a href='/topic/show?id=30fc1282896' target=_blank style='color:#2F92EE;'>#Nivolumab#</a> <a href='/topic/show?id=c3aa4e516d6' target=_blank style='color:#2F92EE;'>#尿路上皮癌#</a> <a href='/topic/show?id=a1231090e19a' target=_blank style='color:#2F92EE;'>#Sitravatinib#</a>, objectTitle=Eur Urol Oncol：Sitravatinib联合Nivolumab治疗晚期或转移性尿路上皮癌患者的2期研究, objectType=article, longId=806767, objectId=65d7806e67d9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20231224/1703402647420_1935437.jpg, objectUrl=/article/show_article.do?id=65d7806e67d9, replyNumber=0, likeNumber=93, createdTime=2023-12-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=65d7806e67d9, moduleTitle=Eur Urol Oncol：Sitravatinib联合Nivolumab治疗晚期或转移性尿路上皮癌患者的2期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65d7806e67d9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2118395, encodeId=c980211839570, content=<a href='/topic/show?id=f336e29134' target=_blank style='color:#2F92EE;'>#FDA#</a>批准<a href='/topic/show?id=67c61046e460' target=_blank style='color:#2F92EE;'>#LAG-3#</a>抗体<a href='/topic/show?id=383210549e83' target=_blank style='color:#2F92EE;'>#Relatlimab#</a>联合<a href='/topic/show?id=30fc1282896' target=_blank style='color:#2F92EE;'>#Nivolumab#</a>用于不可切除或转移性<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a>的儿童和成人患者, objectTitle=FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者, objectType=article, longId=301197, objectId=1dfe30119ee0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220316/1779a5a6c1344c8d9a3c460c24312058.jpg, objectUrl=/article/show_article.do?id=1dfe30119ee0, replyNumber=0, likeNumber=126, createdTime=2023-03-09, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1dfe30119ee0, moduleTitle=FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1dfe30119ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=953886, encodeId=8193953886e9, content=<a href='/topic/show?id=30fc1282896' target=_blank style='color:#2F92EE;'>#Nivolumab#</a>辅助治疗方案用于晚期<a href='/topic/show?id=ccf410109188' target=_blank style='color:#2F92EE;'>#食管癌#</a>成功，事实上，国内PD-1早就用于食管癌了, objectTitle=NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功, objectType=article, longId=209558, objectId=b719209558c2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202144/1617496918229_2051781.jpg, objectUrl=/article/show_article.do?id=b719209558c2, replyNumber=0, likeNumber=220, createdTime=2021-04-05, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b719209558c2, moduleTitle=NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b719209558c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Nivolumab

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#黑色素瘤# #Ipilimumab# #Nivolumab#

NEJM：Nivolumab联合Ipilimumab新辅助治疗黑色素瘤，半数人达到pCR（NADINA试验）

2024-06-06发表于加利福尼亚

梅斯管理员 (审核中...)

前往app查看评论内容

#细胞因子释放综合征# #Nivolumab# #ipillmumab#

读书报告 | 化疗联合nivolumab和ipillmumab发生细胞因子释放综合征5例报道

2024-03-20发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肾癌# #Ipilimumab# #Nivolumab# #ASCO GU 2024#

ASCO GU 2024：Nivolumab/Ipilimumab在未经治疗的晚期或转移性RCC患者中显示出显著的生存获益（CheckMate-214研究）

2024-01-28发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤# #Nivolumab# #纳武利尤单抗#

Blood Adv：Nivolumab联合剂量调整EPOCH一线治疗外周T细胞淋巴瘤：一项I期研究

2024-01-22发表于加利福尼亚

梅斯管理员 (审核中...)

前往app查看评论内容

#外周T细胞淋巴瘤# #Nivolumab# #EPOCH#

Nivolumab联合剂量调整EPOCH一线治疗外周T细胞淋巴瘤：一项I期研究

2024-01-20发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#Nivolumab# #尿路上皮癌# #Sitravatinib#

Eur Urol Oncol：Sitravatinib联合Nivolumab治疗晚期或转移性尿路上皮癌患者的2期研究

2023-12-24发表于上海

showtest (审核中...)

前往app查看评论内容

#FDA#批准#LAG-3#抗体#Relatlimab#联合#Nivolumab#用于不可切除或转移性#黑色素瘤#的儿童和成人患者

FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者

2023-03-09发表于上海

病毒猎手 (审核中...)

前往app查看评论内容

#Nivolumab#辅助治疗方案用于晚期#食管癌#成功，事实上，国内PD-1早就用于食管癌了

NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功

2021-04-05

科室
- - 订阅+
  - 更多科室
工具
服务